RSS
SIGN IN
AI radiology tools are closest to full autonomy, but the FDA's regulatory framework still assumes human-in-the-loop oversight.
True if FDA grants approval for an AI system to make diagnostic decisions without mandatory physician review.
DermaSensor approval demonstrates FDA willingness to clear AI diagnostic tools in clinical settings
Multiple AI radiology systems outperforming human readers
FDA-cleared AI devices now exceed 1,400 — regulatory pipeline maturing
15-20 AI-designed drugs entering Phase III — regulatory precedents accumulating
Pillar-0 achieves 0.87 AUC across 350+ findings
DermaSensor is a clinician-operated handheld device — AI-assisted, not fully autonomous; does not meet 'fully AI-driven' resolution criterion
Liability frameworks for fully autonomous diagnostic tools still do not exist
AMA lobbying against removal of physician oversight remains active
No FDA pre-submission meeting, advisory panel, or De Novo grant news for fully autonomous systems in 11+ consecutive cycles
EU AI Act enforcement activation increases global regulatory pressure toward human-in-the-loop requirements
Cumulative +20pt drift from 25% initial — base rate anchoring question: DermaSensor is progress but not resolution